Reference : Efficacy and tolerability of lasmiditan, an oral 5-HT(1F) receptor agonist, for the a...
Scientific journals : Article
Human health sciences : Neurology
Efficacy and tolerability of lasmiditan, an oral 5-HT(1F) receptor agonist, for the acute treatment of migraine: a phase 2 randomised, placebo-controlled, parallel-group, dose-ranging study.
Farkkila, Markus [> >]
Diener, Hans-Christoph [> >]
Geraud, Gilles [> >]
Lainez, Miguel [> >]
SCHOENEN, Jean mailto [Centre Hospitalier Universitaire de Liège - CHU > > Neurologie CHR >]
Harner, Nadja [> >]
Pilgrim, Alison [> >]
Reuter, Uwe [> >]
Lancet Neurology
Yes (verified by ORBi)
[en] Administration, Oral ; Adult ; Aged ; Benzamides/administration & dosage/adverse effects ; Dose-Response Relationship, Drug ; Double-Blind Method ; Drug Toxicity ; Female ; Humans ; Kaplan-Meier Estimate ; Male ; Middle Aged ; Piperidines/administration & dosage/adverse effects ; Pyridines/administration & dosage/adverse effects ; Serotonin Receptor Agonists/administration & dosage/adverse effects ; Treatment Outcome ; Young Adult
[en] BACKGROUND: Lasmiditan (COL-144) is a novel, centrally acting, highly selective 5-HT(1F) receptor agonist without vasoconstrictor activity that seemed effective when given as an intravenous infusion in a proof-of-concept migraine study. We aimed to assess the efficacy and safety of oral lasmiditan for the acute treatment of migraine. METHODS: In this multicentre, double-blind, parallel-group, dose-ranging study in 43 headache centres in five European countries, patients with migraine with and without aura and who were not using prophylaxis were randomly assigned (1:1:1:1:1) to treat one moderate or severe attack at home with 50 mg, 100 mg, 200 mg, or 400 mg lasmiditan, or placebo. Study drug and placebo were supplied in identical numbered tablet packs. The randomisation code was generated by an independent statistician. Patients and investigators were masked to treatment allocation. The primary endpoint was dose response for headache relief (moderate or severe becoming mild or none) at 2 h. The primary analysis was done in the modified intention-to-treat population. This study is registered with, number NCT00883051. FINDINGS: Between July 8 2009, and Feb 18, 2010, 512 patients were randomly assigned to treatment, 391 of whom received treatment. 86 patients received placebo (81 included in primary analysis) and 305 received lasmiditan (50 mg n=79, 100 mg n=81, 200 mg n=69, and 400 mg n=68 included in primary analysis). There was a linear association between headache response rate at 2 h and lasmiditan dose (Cochran-Armitage test p<0.0001). Every lasmiditan treatment dose significantly improved headache response at 2 h compared with placebo (lasmiditan 50 mg: difference 17.9%, 95% CI 3.9-32.1, p=0.022; 100 mg: 38.2%, 24.1-52.4, p<0.0001; 200 mg: 28.8%, 9.6-39.9, p=0.0018; 400 mg: 38.7%, 23.9-53.6, p<0.0001). The proportion of patients with treatment-emergent adverse events increased with increasing doses (53/82 [65%], 59/82 [72%], 61/71 [86%], and 59/70 [84%] for lasmiditan 50, 100, 200, and 400 mg, respectively vs 19/86 [22%] for placebo). Most adverse events were mild or moderate in intensity, with 16 of 82 (20%), 23 of 82 (28%), 28 of 71 (39%), and 31 of 70 (44%) of patients on lasmiditan 50, 100, 200, and 400 mg, respectively reporting a severe adverse event compared with five of 86 (6%) on placebo. The most common adverse events were CNS related and included dizziness, fatigue, vertigo, paraesthesia, and somnolence. INTERPRETATION: Oral lasmiditan seems to be safe and effective in the acute treatment of migraine. Further assessment in larger placebo-controlled and triptan-controlled trials are needed to assess the potential role of lasmiditan in acute migraine therapy. FUNDING: CoLucid Pharmaceuticals.
Copyright (c) 2012 Elsevier Ltd. All rights reserved.

File(s) associated to this reference

Fulltext file(s):

Restricted access
Lancet_PDF - copie.pdfPublisher postprint178.04 kBRequest copy

Bookmark and Share SFX Query

All documents in ORBi are protected by a user license.